CH
IBB icon

Canton Hathaway’s iShares Biotechnology ETF IBB Stock Holding History

Canton Hathaway’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.1M Buy
9,961
+1,250
+14% +$251K 0.41% 34
2026
Q2 		$1.66M Sell
8,711
-1,250
-13% -$215K 0.32% 40
2026
Q1 		$1.68M Hold
9,961
– – 0.34% 44
2025
Q4 		$1.68M Hold
9,961
– – 0.32% 38
2025
Q3 		$1.44M Hold
9,961
– – 0.28% 47
2025
Q2 		$1.26M Sell
9,961
-4,500
-31% -$552K 0.26% 47
2025
Q1 		$1.85M Buy
14,461
+4,500
+45% +$610K 0.37% 32
2024
Q4 		$1.32M Buy
9,961
+100
+1% +$14.1K 0.33% 39
2024
Q3 		$1.44M Sell
9,861
-190
-2% -$27.5K 0.36% 35
2024
Q2 		$1.38M Hold
10,051
– – 0.38% 37
2024
Q1 		$1.38M Hold
10,051
– – 0.37% 36
2023
Q4 		$1.36M Sell
10,051
-1,200
-11% -$146K 0.41% 31
2023
Q3 		$1.38M Hold
11,251
– – 0.44% 31
2023
Q2 		$1.43M Sell
11,251
-1,600
-12% -$208K 0.45% 32
2023
Q1 		$1.66M Buy
12,851
+8
+0.1% +$1.05K 0.57% 27
2022
Q4 		$1.69M Sell
12,843
-2,130
-14% -$275K 0.59% 25
2022
Q3 		$1.75M Buy
14,973
+435
+3% +$54K 0.64% 25
2022
Q2 		$1.71M Hold
14,538
– – 0.6% 28
2022
Q1 		$1.89M Sell
14,538
-2,588
-15% -$337K 0.53% 32
2021
Q4 		$2.61M Buy
17,126
+210
+1% +$32.5K 0.71% 26
2021
Q3 		$2.74M Buy
16,916
+1,672
+11% +$281K 0.79% 23
2021
Q2 		$2.5M Buy
15,244
+773
+5% +$119K 0.73% 27
2021
Q1 		$2.18M Buy
14,471
+597
+4% +$94.8K 0.7% 26
2020
Q4 		$2.1M Buy
13,874
+6,568
+90% +$939K 0.71% 26
2020
Q3 		$989K Buy
7,306
+4,016
+122% +$545K 0.41% 35
2020
Q2 		$450K Buy
3,290
+418
+15% +$53.3K 0.29% 41
2020
Q1 		$309K Buy
2,872
+625
+28% +$72K 0.22% 48
2019
Q4 		$271K Hold
2,247
– – 0.14% 73
2019
Q3 		$224K Hold
2,247
– – 0.12% 77
2019
Q2 		$245K Buy
2,247
+500
+29% +$53.2K 0.14% 73
2019
Q1 		$195K Hold
1,747
– – 0.11% 74
2018
Q4 		$168K Buy
1,747
+1,192
+215% +$127K 0.11% 66
2018
Q3 		$68K Buy
+555
New +$65.4K 0.04% 89

Other funds holding IBB

Albion Financial Group
Albion Financial Group Salt Lake City, Utah $1.77B AUM 14.95% 1-Year Est. Return
Generali Investments CEE
Generali Investments CEE Prague, Czech Republic $2.11B AUM 18.35% 1-Year Est. Return
MinichMacGregor Wealth Management
MinichMacGregor Wealth Management Saratoga Springs, New York $620M AUM 32.35% 1-Year Est. Return
Investment House LLC
Investment House LLC Redondo Beach, California $2.25B AUM 30.44% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
NTV Asset Management
NTV Asset Management Charleston, West Virginia $1.08B AUM 23.94% 1-Year Est. Return
Old National Bancorp
Old National Bancorp Evansville, Indiana $5.07B AUM 22.07% 1-Year Est. Return
Redstone Wealth Management
Redstone Wealth Management Oklahoma City, Oklahoma $159M AUM 31.94% 1-Year Est. Return
Folger Nolan Fleming Douglas Capital Management
Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.18B AUM 27.44% 1-Year Est. Return
Decker Retirement Planning
Decker Retirement Planning Levi, Utah $302M AUM 70.25% 1-Year Est. Return

Canton Hathaway's IBB Position: Q3 2026 in Review

Canton Hathaway increased its iShares Biotechnology ETF (IBB) stake by 14% in Q3 2026, buying an estimated $251K and bringing the position to 9,961 shares worth $2.1M. The position accounts for 0.41% of the portfolio, ranked #34.

Canton Hathaway first reported a position in IBB in Q3 2018 and has held it in 33 quarters since. The position peaked at $2.74M in Q3 2021. 303 funds tracked by Wall St. Rank hold IBB as of Q3 2026.

  • Canton Hathaway held 9,961 shares of iShares Biotechnology ETF worth $2.1M as of Q3 2026.
  • Canton Hathaway bought 1,250 iShares Biotechnology ETF shares in Q3 2026, an estimated $251K.
  • iShares Biotechnology ETF made up 0.41% of Canton Hathaway's portfolio in Q3 2026, its #34 holding.
  • Canton Hathaway first reported a position in iShares Biotechnology ETF in Q3 2018 and has held it in 33 quarters since.
  • Canton Hathaway's iShares Biotechnology ETF position peaked at $2.74M in Q3 2021.
  • 303 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.

Based on Canton Hathaway's 13F filing for Q3 2026, filed 23 Oct 2026.